ECAT Calls on TB Alliance to Withdraw Patent Applications on Pretomanid and Launches Signature Campaign for Open Letter
On World Tuberculosis Day, the Eurasian Community for Access to Treatment (ECAT) has issued an official letter to the TB Alliance, urging the organization to withdraw its patent applications on the drug pretomanid, or to officially waive any intellectual property rights related to this essential medicine used in the treatment of multidrug-resistant tuberculosis (MDR-TB).